New CBD-Infused Chewing Gum Promises Enhanced Bioavailability —

REDONDO BEACH, CA–(Marketwired – Mar 2, 2017) –, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing AXIM® Biotechnologies Inc.’s ( OTCQB : AXIM ) recently announced improvements to its flagship controlled-release cannabidiol (CBD) functional chewing gum.

Cannabis may be a Schedule I Controlled Substance with ‘no medical benefit’ in the eyes of the Drug Enforcement Administration (DEA), but a growing number of clinical trials have proven that very real benefits exist. Cannabinoids may have anecdotal benefits when it comes to treating a variety of medical conditions, but effective treatments will require non-invasive delivery systems that provide a high level of bioavailability for CBD and other cannabinoids. These delivery systems have increasingly become an area of focus within the therapeutic side

... read more at: